1. Avinger

    0 Comments Leave a Comment

    1-15 of 63 1 2 3 4 5 »
    1. Mentioned In 63 Articles

    2. Beyond Better Clinical Care: Optical Coherence Tomography's Economic Impact

      Beyond Better Clinical Care: Optical Coherence Tomography's Economic Impact
      The optical coherence tomography (OCT) industry has grown dramatically in its first 25 years, and while the positive effects on patient clinical care are the most important measure of OCT's success, its contributions to the economy in jobs, tax receipts, and healthcare savings are also noteworthy. The field of optical coherence tomography (OCT) has grown dramatically since its discovery in the early 1990s. The commercialization and growth of OCT ...
      Read Full Article
    3. Highmark Health’s VITAL Program to Evaluate Avinger’s Novel Treatment for Peripheral Artery Disease

      Highmark Health’s VITAL Program to Evaluate Avinger’s Novel Treatment for Peripheral Artery Disease
      Highmark Health, Allegheny Health Network (AHN) andAvinger, Inc. (NASDAQ:AVGR) announced a collaboration today to evaluate Pantheris, Avingers novel image-guided atherectomy device for the treatment of peripheral artery disease (PAD). The partnership is part of Highmark Healths VITAL (Verification of Innovation by Testing, Analysis and Learning) Innovation Program. Pantheris, which recently received 510(k) clearance from the United States Food Drug Administration (FDA), represents an important leap forward in atherectomy ...
      Read Full Article
      Mentions: FDA Avinger
    4. Atherectomy catheters with longitudinally displaceable drive shafts

      Atherectomy catheters with longitudinally displaceable drive shafts
      Described herein are atherectomy catheters, systems and methods that include longitudinally displaceable drive shafts that drive actuation of one or more cutters at the distal end of the catheter. The catheters described herein may include one or more imaging sensors for imaging before, during or after cutting tissue. In some variations the imaging sensor may be rotated around the perimeter of the catheter independently of the rotation of the cutter ...
      Read Full Article
    5. Atherectomy catheter drive assemblies

      Atherectomy catheter drive assemblies
      A drive assembly for driving an imaging catheter has a rotatable fiber and a rotatable drive shaft. The drive assembly includes a fiber optic rotating junction and a motor configured to rotate the rotatable portion of the fiber optic rotating junction. In some embodiments, the drive assembly includes a sensor configured to detect a rotational position of the fiber optic rotating junction and a processor configured to obtain the detected ...
      Read Full Article
      Mentions: Avinger
    6. New device gives doctors better insight into leg artery blockages

      New device gives doctors better insight into leg artery blockages
      Allegheny General Hospital surgeons are using a newly approved medical device to clear blockages in leg arteries as part of a program to speed technological developments to clinical use. The device, called Pantheris, treats peripheral artery disease, in which plaque builds up in arteries and impedes blood flow. The device uses laser fiber attached to a catheter to help surgeons visualize and remove the plaque with more precision than prior ...
      Read Full Article
    7. 1-15 of 63 1 2 3 4 5 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Avinger

    Avinger

    Avinger Inc was founded in 2007 by John B. Simpson, Ph.D., M.D., Avinger, Inc. is developing the next generation of catheter-based technologies for the treatment of cardiovascular and peripheral vascular disease, utilizing our core competencies in medical device catheter engineering and intravascular imaging.  Avinger acquired Sawtooth Laboratories  in 2010.

  3. Quotes about Avinger

    1. The CE Mark approval for Wildcat is a huge step for Avinger and our dedication to helping the millions of afflicted PAD patients worldwide...With the rate of PAD in Europe closely rivaling the U.S., more and more patients are confronted with the threat of amputation and quality-of-life issues resulting from invasive bypass surgery. We are thrilled to be one step closer to our goal of empowering physicians everywhere with the most advanced tools and technologies to perform the least invasive procedures for PAD sufferers around the globe.
      John B. Simpson in Avinger Receives CE Mark Approval for Its Wildcat Catheter for the Treatment of Peripheral Artery Chronic Total Occlusions and Will Present Results from Its Connect Study at EuroPCR Conference May 17-19
    2. Ocelot CE Mark is a long anticipated milestone for Avinger and a much larger milestone for me professionally. I’ve been working on uniting intravascular guidance with therapeutic products for 30 years and I’m humbled that we’ve been able to achieve this at Avinger... This speaks volumes about our team at Avinger and their dedication to patient care. Ocelot CE Mark is a pivotal step that allows us to immediately help more patients suffering from PAD.”
      John B. Simpson in Avinger Receives CE Mark Approval for Its Ocelot Catheter That Incorporates Real-Time Intravascular Guidance Using Optical Coherence Tomography (OCT)
    3. This is a major milestone for Avinger and a true testament to the perseverance of all our employees and investors. Many people said we couldn't do it...Ocelot and CONNECT II is our first step toward incorporating intravascular imaging into therapeutic catheters. We truly believe this will revolutionize the treatment of vascular disease and amputation prevention.
      John B. Simpson in Avinger Enrolls First European PAD Patient in CONNECT II Global Clinical Trial